Clik here to view.
Modalis Obtains Access to Foundational CRISPR IP
TOKYO & CAMBRIDGE, Mass. Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has...
View ArticleClik here to view.
武田采用高管薪酬追回政策
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502/NYSE:TAK)（“武田”）今天宣布，其董事会批准了一项高管薪酬追回政策（“追回政策”）。该追回政策的采纳是武田为进一步加强其一流公司治理承诺所作不懈努力的一部分，并且与武田的同业一致。...
View ArticleClik here to view.
Promega GoTaq® Probe 1-Step RT-qPCR System Approved for Use in CDC’s COVID-19...
MADISON, Wis. Promega Corporation’s GoTaq® Probe 1-Step RT-qPCR System is now in a Centers for Disease Control and Prevention COVID-19 diagnostic protocol for emergency use. The Promega tool is an...
View ArticleClik here to view.
武田ADCETRIS® (brentuximab...
马萨诸塞州剑桥和日本大阪 (美国商业资讯)– 武田药品工业株式会社(TSE:4502/NYSE:TAK)（“武田”）今天宣布，欧洲药品管理局(EMA)人用药品委员会(CHMP)对ADCETRIS® (brentuximab...
View ArticleClik here to view.
武田薬品、未治療の全身性未分化大細胞リンパ腫成人患者を治療するためのアドセトリス（ブレンツキシマブ・ベドチン）とCHP（シクロホスファミド+ドキソルビシン...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials...
TOKYO CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device “Digital Therapeutics” mobile applications, has launched a Phase 3...
View ArticleClik here to view.
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) extended the current marketing authorization of...
View ArticleClik here to view.
Smart Eye Camera Got Listed in the Valued Supplier List of IAPB for the First...
TOKYO OUI Inc., announced today that our medical device Smart Eye Camera (SEC), a smartphone attachment which functions as a conventional slit-lamp microscope and able to record the ophthalmological...
View ArticleClik here to view.
Cullgen Announces Publication of Small Molecule BRAF Protein Degraders in...
SAN DIEGO Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced...
View ArticleClik here to view.
Esri携手联合国为各国提供COVID-19数据资源
加州雷德兰兹 (美国商业资讯)–全球位置情报的领导者Esri今天宣布，公司将与联合国经济和社会事务部统计司合作，向成员国提供测绘与分析技术，从而帮助成员国在抗击新冠疫情时有效实现必要数据的访问和可视化。这些国家现可利用相关软件和工具，加入COVID-19数据中心联合网络。一个数据中心就是一个基于云的社区参与平台，可通过信息驱动手段组织人员、数据和工具。 联合国经社事务部统计司司长Stefan...
View ArticleClik here to view.
LFB宣布FDA核准新的重组VIIa凝血因子SEVENFACT®，用于治疗伴抑制因子的成人和青少年血友病A或B患者
法国于利斯 –(美国商业资讯)–LFB今天宣布，美国食品药品管理局(FDA)已核准SEVENFACT®的生物制剂许可申请(BLA) 2061，SEVENFACT®是一种新型重组VIIa凝血因子[（重组）VIIa凝血因子-jncw]，用于治疗和控制伴有抑制因子（中和抗体）的成人和12岁及以上青少年血友病A或B患者发生的出血发作。LFB和US WorldMeds的合资企业HEMA...
View ArticleClik here to view.
LFB、新しい組み換え型血液凝固第VIIa因子をインヒビター保有血友病A／Bの成人／青年患者の治療薬としてSEVENFACT®をFDAが承認と発表
仏レジュリス — （ビジネスワイヤ） —...
View ArticleClik here to view.
Clik here to view.
PharmaCyte Biotech Enters into License Agreement for COVID-19 Diagnostic Kits
LAGUNA HILLS, Calif. PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation...
View ArticleClik here to view.
欧盟委员会核准武田ALUNBRIG® (brigatinib)用于ALK+ NSCLC一线治疗
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited) (TSE:4502/NYSE:TAK)今天宣布，欧盟委员会(EC)扩大了ALUNBRIG...
View ArticleClik here to view.
欧州委員会が武田薬品のALUNBRIG®（ブリガチニブ）をALK+ NSCLCのファーストライン治療薬として承認
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
自治医科大学和CureApp, Inc.：首个Digital Therapeutics治疗高血压的3期临床试验在日本启动
东京 (美国商业资讯)–开发了软件式医疗器械Digital Therapeutics移动应用程序的公司CureApp, Inc.（总部：东京都中央区；总裁兼首席执行官：Kohta Satake, M.D.）已联合多名合作伙伴在日本启动Digital Therapeutics治疗高血压的3期多中心随机对照研究（临床试验），其中包括自治医科大学(Jichi Medical...
View ArticleClik here to view.
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a...
PASADENA, Calif. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-ENaC, the company’s...
View ArticleClik here to view.
Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with...
TORONTO & SINGAPORE Cyclica announces a multi-year and multi-project collaboration with the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and...
View Article